Standard BioTools shares surge 10.94% premarket after reporting $185M full-year 2025 revenue and $550M cash outlook post-SomaLogic sale.

Standard BioTools (NASDAQ: LAB) surged 10.94% in premarket trading following the announcement of preliminary 2025 revenue results and strategic updates. The company reported Q4 2025 combined revenue of $56 million and full-year revenue of $185 million, exceeding guidance. Management highlighted cost-cutting initiatives that improved operational efficiency and positioned the business for positive adjusted EBITDA. Additionally, the pending sale of SomaLogic to Illumina, expected to close in H1 2026, will provide $550 million in cash, enhancing strategic flexibility for M&A. These results and forward-looking plans reinforced investor confidence in the company’s path to profitability and long-term growth.